China's NMPA approves JW Therapeutics' Carteyva® for relapsed/refractory Mantle Cell Lymphoma.
China approves first cell therapy for relapsed or refractory Mantle Cell Lymphoma. JW Therapeutics' Carteyva®, a CD19 autologous chimeric antigen receptor T (CAR-T) cell immunotherapy product, receives approval from China's National Medical Products Administration (NMPA) for treating adult patients with relapsed or refractory mantle cell lymphoma (r/r MCL). The approval is based on a pivotal clinical study showing high response rates and safety profile.
August 27, 2024
183 Articles